biostudies-literatureUnknown193(6)Mistry KCancer Research UK<h4>Background</h4>Inadequacy of testing for melanoma BRAF status results in delayed access to systemic therapy. BRAF mutations and their association with patient/tumour characteristics and survival is poorly understood.<h4>Objectives</h4>To report national data from England on the frequency of molecular BRAF testing; the association of patient/tumour characteristics with BRAF mutations; and the treatment and survival of patients with BRAF mutations.<h4>Methods</h4>This national retrospective cohort study identified all new melanomas and molecular BRAF testing in England diagnosed from 2016 to 2021 using population-based data from the National Disease Registration Service. Multivariate logistic regression determined the association between BRAF testing with patient/tumour characteristics aThe British journal of dermatology1146-1154https://www.ebi.ac.uk/biostudies/studies/S-EPMC12626136biostudies-literatureA national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.PMC12626136Bright CMcRonald FJeffrey PPethick JTaylor SKennedy ORichardson KLavelle KMistry KRagan JCraig PLorigan PVenables ZCLevell NJVernon SKarponis DHardy SfalseA national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.<h4>Background</h4>Inadequacy of testing for melanoma BRAF status results in delayed access to systemic therapy. BRAF mutations and their association with patient/tumour characteristics and survival is poorly understood.<h4>Objectives</h4>To report national data from England on the frequency of molecular BRAF testing; the association of patient/tumour characteristics with BRAF mutations; and the treatment and survival of patients with BRAF mutations.<h4>Methods</h4>This national retrospective cohort study identified all new melanomas and molecular BRAF testing in England diagnosed from 2016 to 2021 using population-based data from the National Disease Registration Service. Multivariate logistic regression determined the association between BRAF testing with patient/tumour characteristics a2025-01-01T00:00:00Z2025 Nov2026-06-05T16:04:34.465Z2026-05-18T03:12:44.395ZS-EPMC126261364090209110.1093/bjd/ljaf351